Sustained levodopa therapy in tardive dyskinesia

Sir: The pathophysiology of tardive dyskinesia is still poorly understood, but striatal post-synaptic dopamine receptor hypersensitivity may be implicated.1 Permanent discontinuation of the offending neuroleptic offers the best hope of relief, but the patients' mental state often precludes this. Tetrabenazine is the most effective drug treatment, but side-effects including sedation, depression, Parkinson's syndrome and akathisia are common. The longterm administration of levodopa to rodents has recently been shown to attenuate the behavioural and biochemical features of dopaminergic hypersensitivity.2,3 Promising results have also been reported in tardive dyskinesia giving sustained levodopa treatment4 or small doses of dopamine receptor agonists.4 In view of these findings we have been encouraged to extend this approach to the treatment of patients with irreversible, persistent dyskinesia no longer receiving neuroleptics.

Seven patients (six female, one male) with moderate or severe tardive dyskinesia agreed to participate. Their mean age was 69 years (range 53–93) and the mean duration of involuntary movements was 7 years (range 3–12). Neuroleptics had been given for a mean period of 9-2 years (range 3–30) for schizophrenia, save for three with chronic dyspepsia, agoraphobia and depression respectively. Their conditions were static and their movement disorders comprised a bucco-linguo-masticatory syndrome in seven, additional limb chorea in five and torticollis in one. Two had coexistent akathisia, but none had Parkinson's disease. With one exception all had discontinued neuroleptics for at least one year (mean 4 yr) before the trial. Baseline clinical assessments were made by two independent observers using the AIM scale5 and dyskinesia was recorded simultaneously on video tape. Levodopa 300 mg daily in combination with benserazide was then gradually introduced (Madopar 125, 1 capsule 8 hourly) and the patients assessed at 14 day intervals by the same observers. After a minimum of 12 weeks sustained therapy, patients were re-filmed and the levodopa then discontinued abruptly. Follow-up observation continued for six months with AIM scale scoring.

An initial aggravation of the dyskinesias was seen in one patient following levodopa introduction, but otherwise no significant changes in dyskinesia severity occurred at any stage of the trial.

These disappointing results do not compare favourably with those obtained by Bjornadal and colleagues who reported modest improvement in drug-free patients following one month's levodopa therapy.6 Benefit has also been claimed with chronic levodopa in patients still receiving neuroleptics7 or in those who have just stopped them.8 Casey et al.,9 however, using very large doses of levodopa in combination with benserizide for treatment periods of 8 weeks failed to produce benefit in five neuroleptic treated schizophrenics with tardive dyskinesia. In contrast to other studies we also failed to demonstrate an initial increase in dyskinesia following levodopa introduction.7 Further studies using dopamine receptor agonists and large doses of levodopa in this refractory group of incapacities are now under way.

R J HARDIE
AJ LEES
GM STERN
Department of Neurology,
University College Hospital,
London WC1 6AU, UK

References
Sustained levodopa therapy in tardive dyskinesia.

R J Hardie, A J Lees and G M Stern

J Neurol Neurosurg Psychiatry 1983 46: 685
doi: 10.1136/jnnp.46.7.685

Updated information and services can be found at:
http://jnnp.bmj.com/content/46/7/685.1.citation

Email alerting service
These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/